

Transparency Advisory Group

August 16, 2016

Welcome and Introductions



TAG Goals

1. TAG to approve a process by March 30, 2016 for office based medical provider data review and feedback for anticipated publication of quality data to be published starting Summer 2016.
2. Ensure the dissemination of maternity data by facility to public facing entities that can use the data to inform care decisions by June 30, 2016.
3. Ensure 6 key groups are aware of and actively soliciting use of APCD data; we are seeing more data requests and assessing gaps in the utility to these groups: Payers, Researchers, Employers, Providers, Quality Improvement entities, and Public Health.
4. Advance the breadth of Utah APCD submission data , adding uninsured patient data with FQHC pilot clinics and UHIN as well as successful advancement of Medicare Data in the APCD: evaluate all options for accessing Medicare A & B data and developing a plan to make that information available to users of the APCD by December 31,2016 .
5. TAG to review and develop use cases for dental data for patient information on dental prices for common procedures for insured patients by December 31, 2016
6. TAG to inform the use of APCD data on public health strategies on controlled substance overprescribing and harm by August 30, 2016.



Goal 2: Maternity Data/UtahHealthScape Website Updates

Next set of Quality Metrics and Timeline

APCD Quality Measures

Measures for Comparison Reporting in 2016-2017



2014 Quality Comparison Measures

Comprehensive Diabetes Care: Hemoglobin A1c (HbA1c) Testing (NQF 0057)

Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (NQF 0058)

Breast Cancer Screening (NQF 2372)

The percentage of women 50-74 years of age who had a mammogram to screen for breast cancer.

Well-Child Visits in the First 15 Months of Life (NQF 1392)

The percentage of children 15 months old who had the recommended number of well-child visits with a PCP during their first 15 months of life.

Chlamydia Screening in Women (CHL) (NQF 0033)

The percentage of women 16–24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement year.

Additional Quality Measures

Cervical Cancer Screening (CCS) (NQF 0032)

Percentage of women 21–64 years of age who were screened for cervical cancer using either of the following criteria:

- Women age 21–64 who had cervical cytology performed every 3 years.
- Women age 30–64 who had cervical cytology/human papillomavirus (HPV) co-testing performed every 5 years.

Comprehensive Diabetes Care: Medical Attention for Nephropathy (NQF 0062)

The percentage of patients 18-75 years of age with diabetes (type 1 and type 2) who received a nephropathy screening or monitoring test or had evidence of nephropathy during the measurement year.

Use of Imaging Studies for Lower Back Pain (NQF 0052)

The percentage of members with a primary diagnosis of low back pain who did not have an imaging study (plain x-ray, MRI, CT scan) within 28 days of the diagnosis.

Additional Quality Measures

Medication Management for People with Asthma (MMA) (NQF 1799)

The percentage of patients 5-64 years of age during the measurement year who were identified as having persistent asthma and were dispensed appropriate medications that they remained on during the treatment period. Two rates are reported.

1. The percentage of patients who remained on an asthma controller medication for at least 50% of their treatment period.
2. The percentage of patients who remained on an asthma controller medication for at least 75% of their treatment period.

Persistent Beta Blocker Treatment After a Heart Attack (NQF 0071)

The percentage of patients 18 years of age and older during the measurement year who were hospitalized and discharged from July 1 of the year prior to the measurement year to June 30 of the measurement year with a diagnosis of acute myocardial infarction (AMI) and who received persistent beta-blocker treatment for six months after discharge.

Full List of Available Quality Measures

Comprehensive Diabetes Care: Hemoglobin A1c (HbA1c) Testing (NQF 0057)

Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (NQF 0058)

Breast Cancer Screening (NQF 2372)

Well-Child Visits in the First 15 Months of Life (NQF 1392)

Chlamydia Screening in Women (NQF 0033)

Cervical Cancer Screening (NQF 0032)

Comprehensive Diabetes Care: Medical Attention for Nephropathy (NQF 0062)

Use of Imaging Studies for Lower Back Pain (NQF 0052)

Medication Management for People with Asthma (NQF 1799)

Persistent Beta Blocker Treatment After a Heart Attack (0071)

Survey for Top 3 Metrics

Please reply by August 31 , 2016 and send to any organizations that may have interest to reply

<https://www.surveymonkey.com/r/OHCSqualitymetrics>

Updates from Health Data Committee

**Next Meeting –
What hot topics should we talk about?**

Wrap Up & Next Steps

Next TAG Meeting:
September 20, 2016